Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MeiraGTx nets $70.7mm through FOPO

Executive Summary

UK gene therapy start-up MeiraGTx Holdings PLC (specializes in viral vector design and optimization, manufacturing, and gene regulation technology) netted $70.7mm through the public sale of 3.2mm ordinary shares at $23.50. The company will use the proceeds to fund ongoing development of its pipeline--which has six candidates in the clinic as well as preclinical and research programs--and expand its manufacturing capabilities, with plans to add a second viral vector facility outside the UK and a GMP plasmid production facility.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies